MDSpire - MDSpire Home

MDSpire - MDSpire Home

Region

United States US publications and network International Global sites and content

The premier global destination for healthcare professionals looking for trusted clinical content, breaking news, and a wealth of educational resources.

Conexiant.com
Conexiant Education

Trusted by leading healthcare organizations to deliver measurable engagement, education, and brand growth.

Conexiant Solutions
Conexiant DXP

MDSpire is an innovative platform aiming to create a smarter, faster, and more connected medical community.

MDSpire.com
DentalSpire.com

Association Partner

Our vision is a world free from digestive diseases. That's why it's our mission to empower clinicians and researchers to improve digestive health.

gastro.org
agau.org.gastro
myaga.gastro.org
foundation.gastro.org
agajournals.org
healthecareers.com

Conexiant.com
Conexiant Education

Conexiant DXP

MDSpire.com
DentalSpire.com

gastro.org
myaga.gastro.org
agajournals.org
agau.org.gastro
foundation.gastro.org

Advertisement

What is MDSpire?

MDSpire is an innovative platform aiming to create a smarter, faster, and more connected medical community.

Learn More

Choose specialties Cardiology Dermatology Endocrinology Family Medicine Gastroenterology Hematology Internal Medicine Neurology ObGyn Oncology Ophthalmology Optometry Pediatrics Rheumatology Pulmonary Psychiatry Pathology Surgery Orthopedic Medicine Radiology Otolaryngology Infectious Disease

The Pathologist

June 9, 2026

Pathologist Perspectives on PD-L1 CPS Scoring in Challenging Cases.

June 9, 2026
1 min

Summary
Takeaways
Insight Report
Quiz
Clinical Scorecard

Objective: To provide expert insights into CPS scoring in challenging cases across different indication types. Key Findings: Indication-specific staining charac

Dr. Georgios Deftereos provides expert insights on CPS scoring in challenging pathology cases.
The presentation covers indication-specific staining characteristics affecting CPS evaluation.
Scoring demonstrations are included to enhance understanding of CPS evaluation.
Tips for accurate and efficient evaluation of CPS scoring will be shared.
An interactive Q&A session will allow for discussion and clarification of concepts.

Get a structured, in-depth report that distills clinical articles into clear insights, data, and analysis for deeper learning.

Read Full Report

Get a concise, at-a-glance scorecard that distills clinical guidelines into key recommendations, patient insights, and treatment considerations.

Get quick, clinically relevant Q&A that turns long-form articles into clear answers for faster learning and discovery.

The Ophthalmologist

May 8, 2026

Retinal Ischemia as Stroke Warning

May 8, 2026
3 min

Summary
Takeaways

Acute ischemic ocular events (IOEs), such as retinal artery occlusion (RAO) and amaurosis fugax, are critical indicators of potential cerebrovascular events, as

IOEs indicate high cerebrovascular risk.
22.8% develop ischemic stroke/TIA post-IOE.
Same-day cerebrovascular events occur in 9.4% of cases.
Carotid artery stenosis greatly increases stroke risk.
Urgent referral for stroke evaluation is crucial.
Structured follow-up is necessary.
Vascular assessment should be standard care.
Integration between ophthalmology and stroke services is essential.

The ASCO Post

May 8, 2026

Acupuncture for Nocturia in Survivors of Prostate Cancer

Kevin Liou
May 8, 2026
9 min

Summary
Takeaways

Nocturia, prevalent among prostate cancer survivors, significantly impacts quality of life and increases mortality compared to the general population. Current t

Nocturia affects two-thirds of prostate cancer survivors.
Current treatments for nocturia show weak evidence.
Acupuncture was tested against usual care in a pilot trial.
60 prostate cancer survivors participated in the study.
Acupuncture resulted in a significant reduction in nocturia episodes.
Findings suggest acupuncture is a viable treatment option.
Further studies are needed to solidify results.
Most adverse events were mild in the acupuncture group.

The ASCO Post

May 8, 2026

Patient Care Is Not What We Do, But What Patients Perceive

MUHAMMAD RAFIQUL ISLAM
May 8, 2026
7 min

Summary
Takeaways

Dr. Muhammad Rafiqul Islam emphasizes the significance of patient perceptions in healthcare, particularly in resource-constrained environments like Bangladesh.

Patient perceptions impact healthcare outcomes.
Trust and communication are vital for effective care.
Patient satisfaction is often low in Bangladesh's healthcare system.
Patient-centered care models align treatment with personal values.
Interactions are often brief, making connection challenging.
PREMs and PROMs are essential evaluation tools.
Better care requires addressing systemic challenges in healthcare environments.

The ASCO Post

May 8, 2026

Gerald Hsu, MD, PhD, Named Editor-in-Chief of the ASCO Educational Book

ASCO
May 8, 2026
2 min

Summary
Takeaways

Gerald Hsu, MD, PhD, has been appointed as the new Editor-in-Chief of the ASCO Educational Book, bringing a wealth of experience as a Professor of Clinical Medi

Gerald Hsu appointed Editor-in-Chief of ASCO Educational Book.
He is a Professor at UCSF and Program Director in Hematology/Oncology.
Dr. Hsu's focus includes hematologic malignancies and oncology education.
He aims to adapt the Educational Book to new formats.
Emphasizes the publication's role in providing insights into oncology's current state.

The ASCO Post

May 8, 2026

National Academy of Medicine Recognizes 100 Newly Elected Members

The ASCO Post Staff
May 8, 2026
10 min

Summary
Takeaways

The National Academy of Medicine has elected new members recognized for their significant contributions to health and medicine, highlighting achievements in adv

New members elected to the National Academy of Medicine for significant contributions.
Aim to tackle public health challenges and promote health equity.
At least 25% membership from non-health fields ensures diversity.
Omar Abdel-Wahab at the forefront of blood cancer research.
PD-1 immunotherapy key advancement by Lieping Chen.
Wendy S. Garrett's work on microbiome-host interactions in cancer.
Over 2,400 members now in the academy, highlighting medical excellence.

The ASCO Post

May 8, 2026

Could AI Be Licensed to Practice Oncology?

Govind Persad
May 8, 2026
8 min

Summary
Takeaways

Utah's pilot program allows AI to autonomously renew prescriptions for chronic conditions, showcasing legal and ethical implications, particularly in oncology s

Utah's AI pilot program autonomously renews chronic medication prescriptions.
AI can draft prior authorization letters and monitor treatment side effects.
Major ethical and legal implications arise from AI in oncology.
Concerns about patient consent and liability allocation exist.
The role of physicians remains critical in verifying AI outputs.
Effective patient monitoring using AI could enhance care quality.
Further exploration of high-risk AI applications is necessary.

The ASCO Post

May 8, 2026

Long-Term Risks Revealed for Older Survivors of Childhood Cancers

Lisa Astor
May 8, 2026
14 min

Summary
Takeaways

Survivors of childhood cancer who reach age 50 face increased risks for premature mortality, subsequent cancers, and chronic conditions, significantly higher th

Over 12% of childhood cancer survivors die after age 50 years.
Risks are notably higher for those treated with radiotherapy.
The primary cause of death is subsequent malignancies.
Survivors report significant chronic health conditions compared to siblings.
The study urges ongoing health surveillance for older survivors.
Females have a higher risk for cardiovascular mortality.
Treatment approaches have evolved to minimize radiotherapy exposure.

The ASCO Post

May 8, 2026

KEYNOTE-905: Perioperative Immunotherapy Regimen Active in Cisplatin-Ineligible MIBC

Chase Doyle
May 8, 2026
6 min

Summary
Takeaways

In a pivotal phase III trial (KEYNOTE-905), combining enfortumab vedotin-ejfv, an antibody-drug conjugate, with the PD-1 inhibitor pembrolizumab significantly e

The KEYNOTE-905 trial examined enfortumab vedotin and pembrolizumab for MIBC.
Significant improvements in event-free and overall survival were reported.
Pathologic complete response rate with the combination was 57.1%.
FDA approved the regimen due to its efficacy.
Nearly 80% of participants were cisplatin-ineligible with higher age/complexities.
Safety profile was manageable, consistent with previous results.
344 patients were randomized in the study.
The treatment impacts surgical outcomes minimally.

The ASCO Post

May 8, 2026

Cardiovascular Effects and Risk Factors Identified With BRAF and MEK Inhibition in Melanoma

Julia Cipriano
May 8, 2026
4 min

Summary
Takeaways

A recent longitudinal cohort study by Glen et al., published in JACC: CardioOncology, highlights the prevalence of cancer therapy-related cardiac dysfunction an

Nearly half of melanoma patients on BRAF/MEK inhibitors develop cardiac dysfunction.
Most cases are mild and not progressive.
Early assessment at 4 weeks is crucial.
Recommended monitoring includes blood pressure and echocardiography.
NT-proBNP levels are higher in patients with cardiac dysfunction.
There is a need for improved risk stratification methods.

The ASCO Post

May 8, 2026

Plasma miR-371a-3p Predicts Recurrence in Stage I Testicular Cancer: Interim Results From the CLIMATE Study

Caroline Helwick
May 8, 2026
11 min

Summary
Takeaways

The CLIMATE study evaluates miR-371a-3p as a novel biomarker for identifying patients with stage I testicular cancer who may require adjuvant therapy after orch

CLIMATE study investigates miR-371 in stage I testicular cancer.
miR-371 shows superior predictive power for relapse over existing markers.
Trial enrolled 200 patients from Australia and New Zealand.
Primary aim: assess miR-371 as a biomarker for minimal residual disease.
Interim results show high positive predictive value for plasma samples.
Effective risk assessment could minimize unnecessary chemotherapy.
External validation and long-term follow-up are necessary.

The ASCO Post

May 8, 2026

AI-Powered, Next-Generation Sequencing Blood-Based Assay Evaluated for Detection of Post-HCT Relapse in AML and MDS

Lisa Astor
May 8, 2026
8 min

Summary
Takeaways

The ACROBAT study revealed that the AI-powered AlloHeme tool significantly improves relapse prediction in patients with acute myeloid leukemia (AML) and myelody

AlloHeme tool shows enhanced sensitivity in relapse prediction post-HCT.
Study involved 285 patients with AML and MDS monitored over 2 years.
Achieved 85% sensitivity and 92% specificity.
Detected relapse a median of 41 days prior to clinical signs.
More effective than standard donor engraftment testing.
Potential for earlier interventions indicated by positive test results.
Compliance with the testing schedule impacted results.

The ASCO Post

May 8, 2026

‘Promising’ Signal Only: ctDNA in Early Breast Cancer Not Yet Ready for Clinical Use

Caroline Helwick
May 8, 2026
8 min

Summary
Takeaways

Circulating tumor DNA (ctDNA) testing for early breast cancer shows potential but lacks interventional trial support to confirm improved patient outcomes. Accor

ctDNA has potential but lacks interventional trial evidence for treatment decisions.
Prognostic associations exist, but clinical utility is uncertain.
Ongoing trials are key to assessing ctDNA effectiveness.
Early clearance suggests improved survival but is not definitive for treatment.
Negative ctDNA does not guarantee no recurrence.
Ultrasensitive assays represent advances in detection.
Clinicians should exercise caution when using ctDNA results in practice.

The ASCO Post

May 8, 2026

Belzutifan/Lenvatinib Outperforms Cabozantinib After Checkpoint Inhibitors in Advanced Renal Cell Carcinoma

Julia Cipriano
May 8, 2026
13 min

Summary
Takeaways

The phase III LITESPARK-011 trial revealed that the combination of belzutifan, a novel HIF-2α inhibitor, with lenvatinib significantly improved progression-free

Belzutifan combines with lenvatinib showed improved PFS in renal cell carcinoma patients post-PD-(L)1 therapy.
Median PFS was 14.8 months for the combination vs 10.7 months with cabozantinib.
Objective response rate was significantly higher at 52.6% vs 39.6%.
Study included patients with advanced clear cell carcinoma previously treated with anti–PD-(L)1 therapy.
Safety profile was comparable but with notable increases in anemia with the combination.
Overall survival favored the combination (34.9 months vs 27.6 months).

The ASCO Post

May 8, 2026

RAS Inhibitor Daraxonrasib in Metastatic Pancreatic Cancer

Caroline Helwick
May 8, 2026
13 min

Summary
Takeaways

Recent advancements in the treatment of advanced pancreatic cancer have emerged, particularly with the development of daraxonrasib, a potent inhibitor targeting

Daraxonrasib targets RAS mutations in pancreatic cancer.
Phase III trial showed median overall survival of 13.2 months.
The drug received Breakthrough Therapy Designation from the FDA.
Combination with gemcitabine/nab-paclitaxel shows promising results.
Treatment-related adverse events include rash and diarrhea.
Ongoing research to compare single-agent vs. combination therapy.
Continued focus on managing toxicity effectively.

The Ophthalmologist

May 8, 2026

Retinal Ischemia as Stroke Warning

May 8, 2026
3 min

Summary
Insight Report
Poll

Objective: To assess the stroke risk following acute ischemic ocular events (IOEs) and their implications for systemic health, emphasizing the critical nature o

Get a structured, in-depth report that distills clinical articles into clear insights, data, and analysis for deeper learning.

Read Full Report

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

Frontiers In Endocrinology

May 8, 2026

Transgenerational exposure to plastics-derived endocrine‐disrupting bisphenol A and its analogs on male infertility: impact of gut dysbiosis and epigenetic regulation

Sanjay Basak
Saikanth Varma
Subhalakshmi Nag
Asim K. Duttaroy
May 8, 2026

Summary
Takeaways
Quiz
Poll

Objective: To review the transgenerational impacts of BPA exposure on male infertility risk and the specific roles of gut microbiota interactions within the gut

Bisphenol A (BPA) exposure is linked to declining male fertility rates, affecting sperm count, motility, and quality.
BPA alters gut microbial composition, leading to dysbiosis, which can impact systemic inflammation and reproductive function.
Transgenerational effects of BPA exposure may cause epigenetic changes that affect male fertility across generations.
BPA mimics hormones and disrupts endocrine signaling, particularly affecting Leydig and Sertoli cells, contributing to infertility.
Understanding BPA's impact on the gut-reproductive axis is crucial for developing strategies to protect male reproductive health.

Get quick, clinically relevant Q&A that turns long-form articles into clear answers for faster learning and discovery.

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

Frontiers In Endocrinology

May 8, 2026

Pathological fracture following minimal trauma as the initial presentation of parathyroid carcinoma–associated hyperparathyroidism in a young man: a case report

Miljanka Vuksanović
Bojan Kovačević
Jelena Kuzmanović
Vladimir Vasić
Ognjen Krčmar
Milica Marjanović Petković
May 8, 2026

Summary
Takeaways
Insight Report
Quiz
Poll
Clinical Scorecard

Objective: To present a case of parathyroid carcinoma manifesting as hyperparathyroidism in a young male, emphasizing the need to recognize endocrine causes in

Parathyroid carcinoma is a rare malignant tumor, accounting for approximately 0.005% of all malignancies and a rare cause of primary hyperparathyroidism.
A 36-year-old man presented with a pathological fracture after minimal trauma, highlighting an atypical initial manifestation of parathyroid carcinoma.
Laboratory evaluation revealed severe hypercalcemia and markedly elevated parathyroid hormone levels, consistent with primary hyperparathyroidism.
Surgical resection confirmed the diagnosis of parathyroid carcinoma, emphasizing the need for careful evaluation in cases of unexplained hypercalcemia.
This case underscores the importance of considering endocrine causes in patients with pathological fractures and recurrent nephrolithiasis.

Get a structured, in-depth report that distills clinical articles into clear insights, data, and analysis for deeper learning.

Read Full Report

Get a concise, at-a-glance scorecard that distills clinical guidelines into key recommendations, patient insights, and treatment considerations.

Get quick, clinically relevant Q&A that turns long-form articles into clear answers for faster learning and discovery.

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

Advertisement

Advertisement

Advertisement

About
Privacy Policy

Follow Us

Author/Creator Name

[Credentials]

[Current title or role]

Affiliations: [Institution, organization]

Specialties: Oncology Hematology

View Full Profile

Contributions:

[brand name]

Content Title Goes Here and it Will Get Clamped at Two line

[author name] July 23, 2025 5 min

[brand name]

Content Title Goes Here and it Will Get Clamped at Two line

[author name] July 23, 2025 5 min

[brand name]

Content Title Goes Here and it Will Get Clamped at Two line

[author name] July 23, 2025 5 min

Show all